Vanguard Asset Management’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$60M Buy
1,028,113
+95,569
+10% +$5.64M 0.04% 380
2026
Q2
$52.3M Buy
932,544
+126,399
+16% +$6.58M 0.04% 397
2026
Q1
$38.7M Buy
+806,145
New +$35.3M 0.03% 426

Other funds holding RPRX

Vanguard Asset Management's RPRX Position: Q3 2026 in Review

Vanguard Asset Management increased its Royalty Pharma (RPRX) stake by 10% in Q3 2026, buying an estimated $5.64M and bringing the position to 1,028,113 shares worth $60M. The position accounts for 0.04% of the portfolio, ranked #380.

Vanguard Asset Management first reported a position in RPRX in Q1 2026 and has held it in 3 quarters since. 702 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Vanguard Asset Management held 1,028,113 shares of Royalty Pharma worth $60M as of Q3 2026.
  • Vanguard Asset Management bought 95,569 Royalty Pharma shares in Q3 2026, an estimated $5.64M.
  • Royalty Pharma made up 0.04% of Vanguard Asset Management's portfolio in Q3 2026, its #380 holding.
  • Vanguard Asset Management first reported a position in Royalty Pharma in Q1 2026 and has held it in 3 quarters since.
  • 702 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.